Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials

CONCLUSION: Abatacept monotherapy (SC and IV) was effective and well tolerated in children with pcJIA when prior MTX use was ineffective or not tolerated. Treatment effects of abatacept appear to be independent of MTX co-administration. Consequently, abatacept monotherapy can be considered for those with prior biologic therapy if MTX use is inappropriate.PMID:37453737 | DOI:10.3899/jrheum.2022-1320

Source: J Rheumatol - July 15, 2023 Category: Rheumatology Authors: Nicolino Ruperto Daniel J Lovell Alberto Berman Jordi Anton Diego Oscar Viola Bernard Lauwerys Maria Elena Rama John Bohnsack Johannes Breedt Michel Fischbach Thomas Lutz Kirsten Minden Mahmood Ally Nadina Rubio-P érez Elisabeth Gervais Riana Van Zyl Rob Source Type: research